Knowledge Graph
Graph explorer
Search resolved entities, walk their edges, and read the sentence behind every one.
Entities25 of 207,987
- large language modeltechnology1,043 mentions
- robotic manipulationmarket824 mentions
- artificial intelligencetechnology739 mentions
- reinforcement learningtechnology491 mentions
- density-functional theorytechnology386 mentions
- Transformertechnology371 mentions
- agentic AItechnology353 mentions
- vision-language-action modeltechnology350 mentions
- U.S. Food and Drug Administrationorganization320 mentions
- Vision-Language Modeltechnology318 mentions
- Microsoftorganization291 mentions
- Googleorganization276 mentions
- NVIDIAorganization264 mentions
- Model Context Protocoltechnology232 mentions
- machine learningtechnology204 mentions
- MarketsandMarketsorganization199 mentions
- Claudeproduct192 mentions
- AI agenttechnology188 mentions
- ChatGPTproduct178 mentions
- Anthropicorganization177 mentions
- integrated sensing and communicationtechnology175 mentions
- Amazon Web Services, Inc.organization174 mentions
- OpenAIorganization172 mentions
- diffusion modeltechnology169 mentions
- IBMorganization163 mentions
Entity
amyotrophic lateral sclerosis treatment
market14 mentionslast seen Nov 5, 2026
Disease area for which ACT for ALS programs provide research and expanded access to investigational therapies.
Relationships 5
- CNM-Au8applies toamyotrophic lateral sclerosis treatment99% confidence3 sources
- neflamapimodapplies toamyotrophic lateral sclerosis treatment99% confidence3 sources
- COYA 302applies toamyotrophic lateral sclerosis treatment99% confidence2 sources
- tazbentetolapplies toamyotrophic lateral sclerosis treatment90% confidence1 source
- investigational therapyapplies toamyotrophic lateral sclerosis treatment85% confidence1 source
Relationship
neflamapimodapplies toamyotrophic lateral sclerosis treatment
99% confidence3 supporting mentions
Either name opens that entity’s relationships.
Sources 3
- filingSEC EDGAROct 29, 2026CervoMed Inc. 8-K: Item 7.01: Regulation FD Disclosure; Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
neflamapimod in DLB, nfvPPA, amyotrophic lateral sclerosis (ALS), or any other indication
- filingSEC EDGAROct 13, 2026CervoMed Inc. 8-K: Item 7.01: Regulation FD Disclosure; Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
Neflamapimod is currently in clinical development for the treatment of dementia with Lewy bodies (DLB), recovery after ischemic stroke, nfvPPA, and amyotrophic lateral sclerosis (ALS)
- filingSEC EDGARSep 28, 2026CervoMed Inc. 8-K: Item 7.01: Regulation FD Disclosure; Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
first patient to be dosed with neflamapimod in the EXPERTS-ALS Phase 2a clinical trial